Shigehito Yamagata
Osaka City University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shigehito Yamagata.
Surgical Laparoscopy Endoscopy & Percutaneous Techniques | 2010
Eiji Ako; Tamami Morisaki; Tsuyoshi Hasegawa; Toshiki Hirakawa; Akiko Tachimori; Kazunori Nakazawa; Shigehito Yamagata; Isao Kanehara; Shigehiko Nishimura; Naoyuki Taenaka
Intussusception is rare in adults and it is difficult to diagnose on admission. We present the case of a 43-year-old woman with the chief complaint of nausea and upper abdominal pain. Abdominal multidetector-row computed tomography showed ileo-ileal small bowel intussusception with an intraluminal soft tissue mass with attenuation numbers suggestive of a lipoma. The patient was treated with a laparoscopic-assisted extracorporeal partial resection of the small bowel including ileal lipoma, followed by a functional end-to-end anastomosis. Histologic diagnosis of the resected tumor, 2.4×2.0×2.0 cm, was an intestinal lipoma. This case serves as the basis of a review of small bowel intussusception in adults secondary to lipomas. It focuses on the utility of multidetector-row computed tomography and the cosmetic, physical, and economic benefits of laparoscopic surgery as well as the rarity of the disease.
Digestive Diseases and Sciences | 2004
Bunzo Nakata; Kazuya Muguruma; Shigehito Yamagata; Kiyotaka Yukimoto; Kiyoshi Maeda; Yukio Nishiguchi; Masaichi Ohira; Yasuyuki Kato; Kosei Hirakawa
We studied the relation between clinicopathological factors and dihydropyrimidine dehydrogenase (DPD) activity in gastric and colorectal carcinomas. Specimens obtained by surgery from 27 gastric and 17 colorectal carcinomas and their normal mucosa were examined. The levels of DPD activity in the gastric carcinomas and their normal mucosa were significantly higher than those in colorectal carcinomas and their normal counterparts, respectively (both Ps<0.0001). The gastric carcinomas had significantly higher DPD activities than their normal mucosa (P = 0.028), but the colorectal carcinomas did not. Among the clinicopathological factors, which included invasion/metastatic status and staging, the only effect was that of the histological differences of gastric cancer on DPD activity. That is, the level of DPD activity of the histologically undifferentiated gastric carcinoma was significantly higher than that of the differentiated type. No prognostic predictive values of DPD were recognized in either gastric and colorectal cancer. In conclusion, the higher DPD activity in gastric cancer than colorectal cancer may be due to the higher DPD activity in the background mucosa of origin, and the higher population of undifferentiated type of histological classification, compared to the colorectal counterparts.
Journal of Cancer Therapy | 2018
Yasutake Uchima; Naoki Aomatsu; Hironari Miyamoto; Takuma Okada; Shigeaki Kurihara; Toshiki Hirakawa; Takehiko Iwauchi; Junya Morimoto; Shigehito Yamagata; Kazunori Nakazawa; Kazuhiro Takeuchi
Introduction: Laparoscopic surgery is widely used for the treatment of colorectal cancer. But anastomotic leakage is one of the most serious complications following laparoscopic low anterior resection (LAR) for rectal cancer. The purpose of this study was to investigate whether transanal drainage tube placement can reduce anastomotic leakage and avoid re-operation after laparoscopic LAR. Methods: Retrospective assessment was performed on 143 patients with rectal cancers who underwent laparoscopic LAR between April 2009 and March 2016. A diverting stoma was not created in all 143 patients. A transanal drainage tube was placed after anastomosis using a double stapling technique, in 90 patients (group TT). In group TT, a 24 Fr. Silicon catheter was inserted into the anus and was placed approximately 20 - 25 cm in the descending colon. Another 53 patients were operated on without a transanal drainage tube (group NTT). Clinicopathological and operative variables, the frequencies of anastomotic leakage and re-operation after leakage were investigated. Results: Between the two groups (Group TT and NTT), age, gender, body mass index, tumor size, Dukes’ stage, the number of Liniar stapler firings for rectal transaction, and the rate of left colic artery preservation were comparable. Intra-operative blood loss and operation time decreased group TT from group NTT (p = 0.07) and all cases with symptomatic leakage in group TT were cured by conservative treatment. There was no side effect of transanal drainage tube (perforation or bleeding of the colon, or deviation of the tube) in Group TT. Conclusions: Transanal drainage tube placement prevents anastomotic leakage after laparoscopic LAR. We regard the transnanal drainage tube to be safe and effective without side effect.
Molecular and Clinical Oncology | 2017
Kenji Tezuka; Tsutomu Takashima; Shinichiro Kashiwagi; Hidemi Kawajiri; Shinya Tokunaga; Seika Tei; Shigehiko Nishimura; Shigehito Yamagata; Satoru Noda; Takeo Nishimori; Yoko Mizuyama; Takeshi Sunami; Katsumi Ikeda; Yoshinari Ogawa; Naoyoshi Onoda; Tetsuro Ishikawa; Shinzoh Kudoh; Minoru Takada; Kosei Hirakawa
Although the concurrent use of anthracycline-containing chemotherapy and taxane with trastuzumab are considered the treatment of choice for the primary systemic therapy of human epidermal growth factor receptor 2 (HER2)-overexpressing early breast cancer, non-anthracycline regimens, such as concurrent administration of docetaxel and carboplatin with trastuzumab, exhibited similar efficacies in a previous study. In addition, tri-weekly treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) resulted in significantly higher response rates and a favorable safety profile compared with standard paclitaxel for metastatic breast cancer patients in another phase III study. Based on these results, a phase I study of combination therapy with nab-paclitaxel, carboplatin and trastuzumab was planned, in order to estimate its efficacy and safety for HER2-overexpressing locally advanced breast cancer. The present study was designed to determine the dose-limiting toxicity (DLT), maximum tolerated dose and recommended dose of this combination treatment in women with HER2-overexpressing locally advanced breast cancer. The starting dose of nab-paclitaxel was 220 mg/m2 (level 1), and the dose was escalated to 260 mg/m2 (level 2). Nab-paclitaxel was administered with carboplatin (area under the curve, 6 mg/ml/min) and trastuzumab tri-weekly. A total of 6 patients were enrolled. Although no DLT was observed during the first cycle, 4 patients developed grade 4 thrombocytopenia, 2 had grade 4 neutropenia and 3 exhibited a grade 4 decrease in hemoglobin levels. In the present phase I study, although no patients experienced DLTs, this regimen was associated with severe hematological toxicities and it was not well tolerated. However, considering the high efficacy and lower risk of cardiotoxicity and secondary carcinogenesis with taxane, platinum and trastuzumab combination therapy, further evaluation of another regimen including weekly administration or a more accurate dose setting should be conducted.
Diagnostic and Therapeutic Endoscopy | 1999
Yukio Nishiguchi; Hiroji Nishino; Kazuhiko Yoshikawa; Mikio Nakamura; Osamu Takaishi; Masatsugu Shiba; Hajime Nakamura; Tsutomu Nomura; Katsumi Ikeda; Masaichi Ohira; Takeshi Asai; Shigehito Yamagata; Kazuhiro Takeuchi; Michio Sowa; Noriko Suzuki
Percutaneous endoscopic gastrostomy (PEG) has been widely accepted for patients who have no swallowing ability but have an intact gut. Its clinical application is mainly for nutritional support and decompression of the intestine in patients with bowel obstruction. In this paper, we report external pancreatic juice drainage through a percutaneous endoscopic drainage tube in a patient with postoperative pancreatic juice leakage. Soon after this procedure, pancreatic juice leakage subsided. This procedure was minimally invasive for the patient and may be a new application of PEG to maintain the good quality of life (QOL) in a patient with pancreatic juice leakage.
Oncology Reports | 2004
Shigehito Yamagata; Bunzo Nakata; Kosei Hirakawa
SpringerPlus | 2016
Tsutomu Takashima; Shinya Tokunaga; Seika Tei; Shigehiko Nishimura; Hidemi Kawajiri; Shinichiro Kashiwagi; Shigehito Yamagata; Satoru Noda; Takeo Nishimori; Yoko Mizuyama; Takeshi Sunami; Kenji Tezuka; Katsumi Ikeda; Yoshinari Ogawa; Naoyoshi Onoda; Tetsuro Ishikawa; Shinzoh Kudoh; Minoru Takada; Kosei Hirakawa
Nihon Rinsho Geka Gakkai Zasshi (journal of Japan Surgical Association) | 2009
Akiko Tachimori; Shigehito Yamagata; Eiji Ako; Isao Kanehara; Shigehiko Nishimura; Naoyuki Taenaka
Anticancer Research | 2018
Tsutomu Takashima; Hidemi Kawajiri; Takeo Nishimori; Seika Tei; Shigehiko Nishimura; Shigehito Yamagata; Shinya Tokunaga; Yoko Mizuyama; Takeshi Sunami; Kenji Tezuka; Katsumi Ikeda; Yoshinari Ogawa; Shinichiro Kashiwagi; Satoru Noda; Naoyoshi Onoda; Tetsuro Ishikawa; Shinzoh Kudoh; Minoru Takada; Kosei Hirakawa; Masaichi Ohira
Journal of Clinical Oncology | 2017
Seika Tei; Tsutomu Takashima; Shinichiro Kashiwagi; Hidemi Kawajiri; Shinya Tokunaga; Shigehiko Nishimura; Shigehito Yamagata; Takeo Nishimori; Yoko Mizuyama; Tsuyoshi Sunami; Kenji Tezuka; Satoru Noda; Katsumi Ikeda; Yoshinari Ogawa; Naoyoshi Onoda; Tetsuro Ishikawa; Shinzoh Kudoh; Minoru Takada; Kosei Hirakawa